42-Month Follow-Up Data of Acalabrutinib Monotherapy in R/R CLL Published 2019-12-09 Download video MP4 360p Download video MP4 720p Recommendations 33:39 Transcranial Magnetic Stimulation: A New Treatment Approach for Psychiatric Disorders 10:03 What are the chemotherapy-free treatment options for lymphoma? 18:31 Celiac disease: Mayo Clinic Radio 1:00:22 Ovarian Cancer: Signs & Symptoms, Early Detection, and Treatment Overview 06:30 Houston woman divorces, then adopts husband after wreck left him with brain damage 01:05 Exploring the Reasons Why Certain Prostate Cancers Are More Aggressive 1:30:26 The Science of Pain Management 35:18 Putin: "I dare you weak people in the West to do anything about it" - Fmr. Ambassador Michael McFaul 01:12 FDA-Approved Oral Hypomethylating Agent Regimen Excites MDS Landscape 1:44:58 Why Sleep Matters 23:14 PK deficiency: An Underrecognized Cause of Chronic Hemolytic Anemia 01:40 Multiple Myeloma Treatment Paradigm Improved Markedly In Recent Years 1:27:19 The Art of Aging Well 01:37 Immunotherapy Combinations Improve Survival in Advanced Renal Cell Carcinoma 01:24 Unmet Needs Remain in the Diffuse Large B-Cell Lymphoma Treatment Paradigm 1:31:24 It's All In Your Head — Longwood Seminar 15:32 Parkinson's, Poker, & Loss 01:31 Exploring the Tazemetostat Approval in R/R Follicular Lymphoma 01:23 ELEVATE-TN Shows Acalabrutinib Is Well-Tolerated in CLL 01:00 New Treatment Regimens Used to Provide Maximum Benefit in Multiple Myeloma Similar videos 18:34 CALQUENCE® (acalabrutinib) ELEVATE-RR and ASCEND Data – Dr Ma, MD 35:31 CLL: BTK Inhibitors in Hematologic Oncology Pathways - Pathway-Guided Choices 19:34 CALQUENCE® (acalabrutinib) R/R CLL MAIC of ASCEND and ALPINE – Dr Skarbnik, MD 27:13 Dr Daniel Landau Presents CALQUENCE Long-Term and Pooled Cardiovascular Safety Data for CLL/SLL 01:22 ASH 2019 Interview - Prof Peter Hillmen - Treatment – patient choice 20:40 CLL: Treatment for BTKi Progressors 1:54:09 Controlling and Conquering CLL 1:14:36 Defying the Odds With Innovation in CLL 1:01:53 Level Up With Personalized Care for CLL/SLL 1:08:20 Lymphoma Research Highlights from ASH 2020 01:41 Sequoia trial: Which subset of patients with CLL/SLL benefits the most from zanubritinib treatment? 1:28:28 Challenges in CLL Management Webinar 57:42 Update on CLL/SLL for Newly Diagnosed Patients | LRF Webinars 03:46 TRANSCEND CLL 004 study 01:44 Chaitra Ujjani, MD, considers how physicians should be thinking about BTK inhibitors in CLL 01:05 Chaitra Ujjani, MD, considers the ideal patient profile for zanubrutinib in RR-MCL 01:08 Constantine Tam, MBBS, MD, considers the role of CAR-T cell therapy in chronic lymphocytic leukemia 50:42 17. Redefining CLL Standard of Care in 2021, Dr. Carol Moreno, Barcelona, Spain More results